Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776519 | 0.96 | NAMPT (0.42) | NAMPTRORCSCN3A | |
| SCHEMBL4777591 | 0.91 | NAMPT (0.43) | NAMPTRORCSCN3A | |
| SCHEMBL4767905 | 0.86 | NAMPT (0.42) | NAMPTRORCSCN3APPARAPPARG | |
| SCHEMBL5569246 | 0.86 | NAMPT (0.42) | NAMPTRORCSCN3APPARAPPARG | |
| SCHEMBL4777334 | 0.81 | SCN3A (0.46) | NAMPTSCN3APPARAPPARGTDP1 | |
| SCHEMBL4769756 | 0.79 | LMNA (0.47) | NAMPTRORCALDH1A1 | |
| SCHEMBL4770850 | 0.79 | NAMPT (0.44) | NAMPTRORCALDH1A1 | |
| SCHEMBL14497666 | 0.79 | EPHX2 (0.62) | NAMPTSCN3APPARAPPARGTDP1 | |
| SCHEMBL4777709 | 0.78 | PPARG (0.48) | NAMPTRORCSCN3APPARAPPARG | |
| SCHEMBL4777412 | 0.78 | EPHX2 (0.46) | NAMPTRORCSCN3APPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-14 | — | — | US | claimed |
| EP-1942888-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| WO-2007056078-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | NAMPT 3369/4885RORC 1743/4885SCN3A 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.